Today, we reported second quarter 2024 financial results and highlighted recent updates. For full details and results, read today’s press release: https://bit.ly/3YELJ0O
Neurogene Inc.
Biotechnology
New York, New York 12,990 followers
Reimagining the future for rare neurological diseases
Über uns
Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families. To do this, we are working with experts across the globe to advance a broad pipeline of programs to treat the underlying cause of serious neurological disorders and thereby address the overwhelming need for new therapies. Although the human genome was sequenced for the first time nearly 20 years ago, the true genomics revolution is taking place now, providing us with the ability to radically alter rare, genetic disorders. At Neurogene, we are working to provide medicines to improve the lives of neurologically-impaired and developmentally-delayed children and their families. We are building a team of passionate, driven individuals who envision a world in which all families have access to genetic medicines, even if the disorder is exceedingly rare. To learn more, please visit http://www.neurogene.com/careers/.
- Website
-
http://www.neurogene.com
External link for Neurogene Inc.
- Industrie
- Biotechnology
- Größe des Unternehmens
- 51-200 Mitarbeiter
- Hauptsitz
- New York, New York
- Typ
- In Privatbesitz
- Gegründet
- 2018
Standorte
-
Primäre
Wegbeschreibung erhalten
535 W 24th St
5. Stockwerk
New York, New York 10011, US
Employees at Neurogene Inc.
Aktualisierungen
-
We are excited to announce that the FDA has granted Regenerative Medicine Advanced Therapy #RMAT designation to NGN-401 for #RettSyndrome. RMAT designation is based on preliminary clinical evidence that a drug has the potential to address unmet medical needs. We look forward to continued collaboration with the FDA as we continue advancing our mission to bring life-changing medicines to those who are impacted by rare neurological diseases. #RMAT #Genetherapy #RettSyndrome To learn more, read today’s press release: https://bit.ly/3T2HyZ9
-
-
Neurogene Inc. reposted this
🥼 Neurogene Inc is on a mission: to improve the lives of patients and families devastated by rare neurological diseases. 🧬 The medicine Neurogene Inc. is creating has the potential to fundamentally change the way these disorders are treated. 🔔 We are so proud to be your partner $NGNE! Thrilled to welcome you to ring the Nasdaq Opening Bell! #NasdaqListed
-
-
Thank you Nasdaq for hosting us for an amazing morning ringing today’s opening bell! Watch the ceremony here: https://bit.ly/4dufaXu #NasdaqBell #NasdaqListed $NGNE #Genetherapy #Biotech
-
On Tuesday, July 9, management will participate in the BMO 2024 Genetic Medicines Summit. To learn more, read our full press release here: https://bit.ly/3L68OBx
-
-
Today, we joined the Russell 3000® Index as part of the Russell indexes annual reconstitution. We are proud of all that we have accomplished that has enabled our addition to this industry benchmarking index. #RussellRecon Read our full press release here: https://bit.ly/4eMgh69
-
-
Tune in today at 10:40 a.m. ET to watch our Founder and Chief Executive Officer, Rachel McMinn, participate in a fireside chat at the TD Cowen Genetic Medicines & RNA Summit. A link to the webcast is available here: https://bit.ly/4c8pYKe
-
-
We are pleased to announce that the first patient has been dosed in the high-dose cohort of our Phase 1/2 trial of NGN-401 in female pediatric patients with #Rettsyndrome, and that high-dose NGN-401 has been well-tolerated thus far. In addition, low-dose NGN-401 continues to demonstrate a favorable safety profile. We are joining the Rett syndrome community to discuss these data at the International Rett Syndrome Foundation ASCEND Summit. Read today’s press release to learn more: https://bit.ly/3XsvGST
-
-
Neurogene Inc. reposted this
Check out this job at Neurogene and join our amazing HR Team!
-
Tune in today at 1:20 p.m. ET to watch our Founder and Chief Executive Officer, Rachel McMinn, present at the Goldman Sachs 45th Annual Global Healthcare Conference. A link to the webcast is available here: https://bit.ly/4bSuYD8
-